• A Corrigendum to this article was published on 17 December 2014


In mammalian cells, the MYC oncoprotein binds to thousands of promoters1,2,3,4. During mitogenic stimulation of primary lymphocytes, MYC promotes an increase in the expression of virtually all genes1. In contrast, MYC-driven tumour cells differ from normal cells in the expression of specific sets of up- and downregulated genes that have considerable prognostic value5,6,7. To understand this discrepancy, we studied the consequences of inducible expression and depletion of MYC in human cells and murine tumour models. Changes in MYC levels activate and repress specific sets of direct target genes that are characteristic of MYC-transformed tumour cells. Three factors account for this specificity. First, the magnitude of response parallels the change in occupancy by MYC at each promoter. Functionally distinct classes of target genes differ in the E-box sequence bound by MYC, suggesting that different cellular responses to physiological and oncogenic MYC levels are controlled by promoter affinity. Second, MYC both positively and negatively affects transcription initiation independent of its effect on transcriptional elongation8. Third, complex formation with MIZ1 (also known as ZBTB17)9 mediates repression of multiple target genes by MYC and the ratio of MYC and MIZ1 bound to each promoter correlates with the direction of response.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


Primary accessions


Gene Expression Omnibus

Data deposits

Microarray data sets have been deposited in ArrayExpress under accession number E-MTAB-1886. All ChIP- and RNA-sequencing data sets have been deposited in the Gene Expression Omnibus under accession number GSE44672.


  1. 1.

    et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 151, 68–79 (2012)

  2. 2.

    et al. Transcriptional amplification in tumor cells with Elevated c-Myc. Cell 151, 56–67 (2012)

  3. 3.

    et al. Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell 133, 1106–1117 (2008)

  4. 4.

    et al. Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc. Natl Acad. Sci. USA 103, 17834–17839 (2006)

  5. 5.

    et al. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J. Exp. Med. 209, 679–696 (2012)

  6. 6.

    et al. Induction of ectopic Myc target gene JAG2 augments hypoxic growth and tumorigenesis in a human B-cell model. Proc. Natl Acad. Sci. USA 107, 3534–3539 (2010)

  7. 7.

    et al. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. Proc. Natl Acad. Sci. USA 109, 19190–19195 (2012)

  8. 8.

    et al. c-Myc regulates transcriptional pause release. Cell 141, 432–445 (2010)

  9. 9.

    et al. The role of MIZ-1 in MYC-dependent tumorigenesis. Cold Spring Harb. Perspect. Med. 3, a014290 (2013)

  10. 10.

    et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 69, 119–128 (1992)

  11. 11.

    et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005)

  12. 12.

    et al. Binding of Myc proteins to canonical and noncanonical DNA sequences. Mol. Cell. Biol. 13, 5216–5224 (1993)

  13. 13.

    & c-Myc mediates activation of the cad promoter via a post-RNA polymerase II recruitment mechanism. J. Biol. Chem. 276, 48562–48571 (2001)

  14. 14.

    & Myc recruits P-TEFb to mediate the final step in the transcriptional activation of the cad promoter. J. Biol. Chem. 277, 40156–40162 (2002)

  15. 15.

    et al. Myc-binding-site recognition in the human genome is determined by chromatin context. Nature Cell Biol. 8, 764–770 (2006)

  16. 16.

    , , , & Myc-induced proliferation and transformation require Akt-mediated phosphorylation of FoxO proteins. EMBO J. 23, 2830–2840 (2004)

  17. 17.

    & The RNA polymerase II CTD coordinates transcription and RNA processing. Genes Dev. 26, 2119–2137 (2012)

  18. 18.

    et al. Miz1 is required to maintain autophagic flux. Nature Commun. 4, 2535 (2013)

  19. 19.

    et al. Repression of p15INK4b expression by Myc through association with Miz-1. Nature Cell Biol. 3, 392–399 (2001)

  20. 20.

    et al. A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF. Cancer Res. 71, 404–412 (2011)

  21. 21.

    et al. Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc. Natl Acad. Sci. USA 98, 4510–4515 (2001)

  22. 22.

    et al. Negative regulation of the mammalian UV response by Myc through association with Miz-1. Mol. Cell 10, 509–521 (2002)

  23. 23.

    et al. Transcription factor Miz-1 is required to regulate interleukin-7 receptor signaling at early commitment stages of B cell differentiation. Immunity 33, 917–928 (2010)

  24. 24.

    et al. The interaction between Myc and Miz1 is required to antagonize TGFβ-dependent autocrine signaling during lymphoma formation and maintenance. Genes Dev. 24, 1281–1294 (2010)

  25. 25.

    et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469–483 (2005)

  26. 26.

    et al. Analysis of c-Myc function in normal cells via conditional gene-targeted mutation. Immunity 14, 45–55 (2001)

  27. 27.

    , , , & Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl Acad. Sci. USA 93, 11382–11388 (1996)

  28. 28.

    & Myc versus USF: discrimination at the cad gene is determined by core promoter elements. Mol. Cell. Biol. 17, 2529–2537 (1997)

  29. 29.

    Aligning short sequencing reads with Bowtie. Curr. Protoc. Bioinformatics 32, 11.7.1–11.7.14 (2010)

  30. 30.

    et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008)

  31. 31.

    , , , & The Integrated Genome Browser: free software for distribution and exploration of genome-scale datasets. Bioinformatics 25, 2730–2731 (2009)

  32. 32.

    et al. seqMINER: an integrated ChIP-seq data interpretation platform. Nucleic Acids Res. 39, e35 (2011)

  33. 33.

    & BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841–842 (2010)

  34. 34.

    , & edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2010)

  35. 35.

    , & Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature Protocols 4, 44–57 (2009)

  36. 36.

    & MEME-ChIP: motif analysis of large DNA datasets. Bioinformatics 27, 1696–1697 (2011)

  37. 37.

    et al. Pol II and its associated epigenetic marks are present at Pol III-transcribed noncoding RNA genes. Nature Struct. Mol. Biol. 17, 629–634 (2010)

  38. 38.

    et al. c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I. Nature Cell Biol. 7, 311–318 (2005)

Download references


This work was funded by the Deutsche Forschungsgemeinschaft (DFG) through grants 222/5-3 and 222/12-1 (to M.E.), by a stipend of the graduate college 1048 (“Molecular basis of organ development in vertebrates” to S.W.) and through the DFG Research Center for Experimental Biomedicine (to E.W.). M.T. was supported by grants from the Institut National Du Cancer (INCa) and by the Ligue National Contre le Cancer (Equipe Labellisée). O.S. and J.M. are funded by a Cancer Research UK core grant and a European Research Council investigator grant, “Coloncan”. We thank Y. L. Lee and T. Poh for help with ChIP-sequencing, F. Finkernagel for help with the bioinformatic analysis, A. Au for help with mouse experiments, B. Lüscher for critical reading of the manuscript and D. Levens for providing data before publication.

Author information

Author notes

    • Susanne Walz
    • , Francesca Lorenzin
    • , Elmar Wolf
    •  & Martin Eilers

    These authors contributed equally to this work.


  1. Theodor Boveri Institute, Biocenter, University of Würzburg, Am Hubland, 97074 Würzburg, Germany

    • Susanne Walz
    • , Francesca Lorenzin
    • , Katrin E. Wiese
    • , Björn von Eyss
    • , Steffi Herold
    • , Elmar Wolf
    •  & Martin Eilers
  2. CRUK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK

    • Jennifer Morton
    • , Saadia Karim
    •  & Owen Sansom
  3. Institute for Molecular Biology and Tumor Research (IMT), Emil-Mannkopff-Str.2, 35033 Marburg, Germany

    • Lukas Rycak
  4. University of Bordeaux, IECB, ARNA laboratory, Equipe Labellisée Contre le Cancer, 33600 Pessac, France

    • Hélène Dumay-Odelot
    •  & Martin Teichmann
  5. Institute for Genetics, Justus-Liebig-University, Heinrich-Buff-Ring 58, 35390 Giessen, Germany

    • Marek Bartkuhn
  6. University Children’s Hospital of Cologne, and Cologne Center for Molecular Medicine (CMMC), University of Cologne, Kerpener Str. 62, 50924 Cologne, Germany

    • Frederik Roels
    •  & Matthias Fischer
  7. University Hospital Tübingen, Division of Translational Gastrointestinal Oncology, Department of Internal Medicine I, Otfried-Mueller-Strasse 10, 72076 Tübingen, Germany

    • Torsten Wüstefeld
    •  & Lars Zender
  8. Translational Gastrointestinal Oncology Group within the German Center for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), 69121 Heidelberg, Germany

    • Lars Zender
  9. DOE Joint Genome Institute, 2800 Mitchell Drive, Walnut Creek, California 94598, USA

    • Chia-Lin Wei
  10. Rudolf Virchow Center/DFG Research Center for Experimental Biomedicine, University of Würzburg, Josef-Schneider-Str.2, 97080 Würzburg, Germany

    • Elmar Wolf
  11. Comprehensive Cancer Center Mainfranken, University of Würzburg, Josef-Schneider-Str. 6, 97080 Würzburg, Germany

    • Martin Eilers


  1. Search for Susanne Walz in:

  2. Search for Francesca Lorenzin in:

  3. Search for Jennifer Morton in:

  4. Search for Katrin E. Wiese in:

  5. Search for Björn von Eyss in:

  6. Search for Steffi Herold in:

  7. Search for Lukas Rycak in:

  8. Search for Hélène Dumay-Odelot in:

  9. Search for Saadia Karim in:

  10. Search for Marek Bartkuhn in:

  11. Search for Frederik Roels in:

  12. Search for Torsten Wüstefeld in:

  13. Search for Matthias Fischer in:

  14. Search for Martin Teichmann in:

  15. Search for Lars Zender in:

  16. Search for Chia-Lin Wei in:

  17. Search for Owen Sansom in:

  18. Search for Elmar Wolf in:

  19. Search for Martin Eilers in:


S.W., F.L., E.W., K.E.W., B.v.E. and T.W. performed the experiments, S.H., H.D.-O. and M.T. characterized the MIZ1 637–807 antibody, S.W., F.L. and E.W. performed ChIP-sequencing experiments, J.M. and S.K. analysed the pancreas model, F.L., F.R., M.B., M.F., S.W. and L.R. performed statistical analyses. E.W., L.Z., O.S., C.-L.W. and M.E. devised and supervised experiments. E.W. and M.E. wrote the paper and should be considered as senior authors of this study.

Competing interests

The authors declare no competing financial interests.

Corresponding authors

Correspondence to Elmar Wolf or Martin Eilers.

Extended data

Supplementary information

Excel files

  1. 1.

    Supplementary Table 1

    Myc- and Myc/Miz1-bound genes in murine fibroblasts, T-lymphoma cells and pancreatic tumour cells. "+" indicates promoters (-1 kb to +0.5 kb) containing a MACS-called peak (FDR<0.1), "-" indicates promoters without Myc or Myc/Miz1 binding site.

  2. 2.

    Supplementary Table 2

    Oligonucleotides used in the study.

About this article

Publication history






Further reading Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.